Cannabis Interstate Commerce: Federal Law, State Conflicts & Industry Impact

Executive Summary

Cannabis interstate commerce — the legal movement of marijuana products across state lines — represents one of the most significant structural shifts in the American cannabis industry since Colorado's first adult-use sales in 2014. For decades, the federal prohibition under the Controlled Substances Act (CSA), codified at 21 U.S.C. § 812, has forced every state-legal cannabis market to operate as an isolated island, with cultivation, processing, testing, and retail confined within state borders. This fragmentation has created profound inefficiencies: California growers face wholesale prices below $300 per pound while East Coast dispensaries pay $3,000-plus for the same quality flower. Multi-state operators (MSOs) maintain redundant cultivation facilities in each jurisdiction, burning capital that could otherwise fund innovation or expansion. In July 2026, Glass House Brands announced what it characterized as the beginning of legal interstate commerce, signaling a potential watershed moment. Whether through federal rescheduling under the Drug Enforcement Administration (DEA), congressional action, or novel legal interpretations of the dormant Commerce Clause, the barriers are beginning to crack. The implications span billions of dollars in capital reallocation, the potential collapse of protected regional markets, and fundamental questions about state sovereignty versus federal supremacy in cannabis regulation.

Why Cannabis Interstate Commerce Matters

The prohibition on interstate cannabis commerce costs the industry an estimated $8-12 billion annually in duplicated infrastructure, inefficient logistics, and artificial price disparities across state lines. Every MSO operating in multiple states must build or lease cultivation facilities, processing labs, and distribution networks in each jurisdiction, even when a single centralized operation could serve multiple markets more efficiently. Curaleaf, Trulieve, Green Thumb Industries, and Verano each maintain 15-25 separate state-level operations, with cultivation footprints ranging from 500,000 to over 2 million square feet of canopy. This redundancy drives up capital expenditure requirements, delays profitability, and creates barriers to entry for smaller operators who cannot afford multi-state replication. Patients and consumers bear the cost. A gram of concentrate testing at 85% THC costs $25-35 in Oregon, where oversupply has crashed wholesale markets, but $80-120 for equivalent product in New York or New Jersey, where supply constraints persist. Medical patients in states with limited cultivation capacity — such as Louisiana, which until recently restricted production to two licensed growers — face access challenges that interstate commerce could immediately resolve. The American Cannabis Operators Coalition estimated in 2025 that interstate commerce could reduce consumer prices by 30-50% in undersupplied markets within 18 months of implementation. The stakeholder map is vast. Cultivators in low-cost production states like Oklahoma, Oregon, and California stand to gain massive new markets, while growers in protected high-price states face potential obsolescence. Testing laboratories, which currently must be licensed in each state, could consolidate. Transportation and logistics companies see a multi-billion-dollar opportunity. State tax authorities worry about revenue leakage if products cross borders. And the federal government faces the challenge of reconciling state-legal commerce with ongoing Schedule I or potential Schedule III classification under the CSA.

Background and History: The Long Road Toward Interstate Cannabis Commerce

The prohibition on cannabis interstate commerce is not explicitly written into any single statute — rather, it emerges from the intersection of the Controlled Substances Act, the Commerce Clause, and state-level seed-to-sale tracking requirements that assume closed-loop systems.

1970: The Controlled Substances Act Creates Federal Prohibition

The CSA, enacted as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, placed cannabis in Schedule I alongside heroin and LSD. Under 21 U.S.C. § 841, the manufacture, distribution, or possession with intent to distribute any Schedule I controlled substance became a federal felony, punishable by up to five years for a first offense and up to 40 years for large-scale operations. The statute makes no exception for state-legal activity. Critically, 21 U.S.C. § 812(b)(1) defines Schedule I substances as having "no currently accepted medical use" and "a high potential for abuse," findings that have remained unchanged for cannabis despite 38 states legalizing medical use by 2024. The Commerce Clause, Article I, Section 8, Clause 3 of the U.S. Constitution, grants Congress the power to "regulate Commerce with foreign Nations, and among the several States." In Gonzales v. Raich (2005), the Supreme Court held 6-3 that the federal government could prosecute individuals growing cannabis for personal medical use under California's Compassionate Use Act, because such cultivation — even if never sold or transported — substantially affects interstate markets in the aggregate. Justice Stevens wrote for the majority that "Congress can regulate purely intrastate activity that is not itself 'commercial'... if it concludes that failure to regulate that class of activity would undercut the regulation of the interstate market." This ruling cemented federal supremacy over state cannabis laws and, by extension, over any state attempt to authorize interstate commerce.

1996-2012: State Medical Programs Emerge in Isolation

California's Proposition 215 in 1996 launched the modern medical cannabis era, but the law contained no provisions for interstate commerce — nor could it, given federal prohibition. Each subsequent state medical program (Oregon in 1998, Colorado and Nevada in 2000, and 30 more by 2024) included explicit language confining all activity to state borders. Colorado's Amendment 20, for example, specified that medical marijuana must be "grown, processed, and dispensed within Colorado." These restrictions were both legal necessity (to avoid federal Commerce Clause scrutiny) and political strategy (to reassure voters that legalization would not turn their state into a national distribution hub).

2013-2018: Cole Memo Era and State Silos Harden

The August 2013 Cole Memo, issued by Deputy Attorney General James Cole, established eight federal enforcement priorities for cannabis, including "preventing the diversion of marijuana from states where it is legal under state law in some form to other states." This guidance explicitly reinforced the prohibition on interstate commerce, signaling that the Department of Justice would tolerate state-legal programs only if they remained hermetically sealed. The memo was rescinded by Attorney General Jeff Sessions in January 2018, but its framework shaped industry structure for a critical growth period. Multi-state operators emerged during this window — Curaleaf, Trulieve, Green Thumb, Cresco Labs — but each built state-by-state operations with no interstate product movement. Seed-to-sale tracking systems like METRC (Marijuana Enforcement Tracking Reporting Compliance), mandated in California, Colorado, Michigan, and 15 other states, were designed on the assumption of closed-loop state markets. Every plant receives a unique RFID tag at the seedling stage, and every transaction — from cultivation to processing to retail — is logged in a state database. The system has no mechanism for interstate transfers, and regulators have consistently interpreted any cross-border movement as diversion subject to criminal penalties.

2020-2022: The STATES Act and Congressional Proposals

The Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, introduced in multiple sessions between 2018 and 2022, proposed amending the CSA to exempt state-legal cannabis activity from federal prohibition. Section 2(a) of the 2021 version stated: "No provision of the Controlled Substances Act shall prohibit or otherwise restrict... the production, distribution, or possession of marihuana... in a State in which such activity is legal." Crucially, the bill included language that would have permitted interstate commerce between states that both authorized it, effectively creating a patchwork system where compliant states could trade while others remained isolated. The bill never advanced beyond committee, but it established a legislative template. The SAFE Banking Act, which passed the House seven times between 2019 and 2023, focused on financial access but included no interstate commerce provisions. The MORE Act (Marijuana Opportunity Reinvestment and Expungement Act), which passed the House in 2020 and 2022, would have descheduled cannabis entirely, removing it from the CSA and thereby eliminating the federal barrier to interstate commerce. It stalled in the Senate both times.

2023-2024: DEA Rescheduling Proceedings Begin

In August 2023, the Department of Health and Human Services (HHS) recommended to the DEA that cannabis be rescheduled from Schedule I to Schedule III, based on a review concluding that cannabis has accepted medical use and lower abuse potential than Schedule I or II substances. The DEA published a Notice of Proposed Rulemaking (NPRM) in May 2024, opening a 60-day comment period that drew over 43,000 submissions. Schedule III substances, which include ketamine, anabolic steroids, and Tylenol with codeine, are subject to the Controlled Substances Act but can be prescribed and, critically, can be manufactured and distributed in interstate commerce by DEA-registered entities under 21 C.F.R. § 1301. If cannabis moves to Schedule III, the legal landscape shifts but does not fully clarify. State-licensed cannabis businesses would still face a conflict: they could not become DEA-registered manufacturers without federal approval, which the DEA has never granted for cannabis. However, the rescheduling could provide legal cover for novel arguments under the dormant Commerce Clause, which prohibits states from enacting laws that unduly burden interstate commerce. In 2025, several legal scholars, including Professor Robert Mikos of Vanderbilt Law School, published analyses suggesting that once cannabis is rescheduled, state laws prohibiting interstate commerce could be challenged as unconstitutional protectionist measures.

2025-2026: Industry Pressure and the Glass House Announcement

By early 2025, the economic pressure for interstate commerce had reached a breaking point. California's wholesale cannabis market saw prices for premium indoor flower drop to $400-600 per pound, while New York dispensaries paid $2,800-3,200 per pound for similar quality. Oklahoma, which issued over 9,000 cultivation licenses in a population of 4 million, faced a glut of over 1 million pounds of unsold inventory. Meanwhile, New Jersey, Maryland, and Ohio struggled with supply shortages that kept retail prices at $50-70 per eighth. In July 2026, Glass House Brands, a vertically integrated California cultivator and retailer, announced what it described as "the age of legal cannabis interstate commerce." The company did not disclose full details of its legal strategy, but industry analysts speculated it could involve a test shipment to a state with reciprocal authorization, a declaratory judgment action in federal court, or reliance on a novel interpretation of the rescheduling proceedings. The announcement sent shockwaves through the industry, with MSO stocks fluctuating sharply as investors weighed the competitive implications.

Key Players in the Interstate Commerce Debate

Drug Enforcement Administration (DEA)

The DEA holds sole authority to reschedule controlled substances under 21 U.S.C. § 811(a). Administrator Anne Milgram, appointed in 2021, has overseen the rescheduling review but has made no public statements endorsing interstate commerce. The agency's historical position, articulated in a 2011 denial of a rescheduling petition, is that cannabis remains a dangerous drug with high abuse potential. If the DEA finalizes Schedule III rescheduling in 2026 or 2027, it will likely issue guidance on whether state-licensed operators can engage in interstate commerce, but legal experts expect the agency to maintain restrictions absent explicit congressional authorization.

Multi-State Operators (MSOs)

The largest MSOs have conflicting incentives. Curaleaf, with operations in 18 states, has invested over $1.2 billion in state-specific infrastructure. Interstate commerce could render much of that investment obsolete if the company could supply multiple markets from a single low-cost cultivation hub. However, Curaleaf also benefits from protected state markets where it holds limited licenses — in New York, for example, the company operates under a restricted-license regime that shields it from out-of-state competition. Trulieve, dominant in Florida with 125+ dispensaries, has publicly opposed federal legalization measures that could enable interstate commerce, fearing California and Oklahoma flower would undercut its vertically integrated model. Smaller MSOs and single-state operators in high-cost markets face existential risk. A Massachusetts cultivator paying $150,000 annually in licensing fees and operating in a state with a 10.75% excise tax cannot compete with Oregon flower grown outdoors at $50 per pound production cost. The National Cannabis Industry Association (NCIA) has not taken a unified position, reflecting deep divisions within its membership.

State Regulators and Tax Authorities

State cannabis control boards in California, Colorado, Washington, and Oregon have expressed cautious interest in interstate commerce, recognizing it could relieve oversupply and stabilize prices. The California Department of Cannabis Control (DCC), which oversees a market with over $5 billion in annual sales, has participated in multi-state working groups exploring reciprocal licensing and product transfer agreements. However, no state has unilaterally authorized outbound shipments, fearing federal preemption and loss of tax revenue. Tax authorities worry that interstate commerce could enable arbitrage. If a California cultivator ships flower to New York, which state collects excise tax — the origin state, the destination state, or both? Without federal coordination, double taxation or tax evasion becomes likely. The Federation of Tax Administrators estimated in 2025 that interstate commerce without a streamlined tax framework could cost states $500 million to $1 billion annually in lost revenue.

Advocacy Organizations

The U.S. Cannabis Council, representing large MSOs, has advocated for federal legislation that includes interstate commerce provisions, but only with "guardrails" such as federal quality standards and state opt-in requirements. The Marijuana Policy Project (MPP) supports interstate commerce as a matter of economic efficiency and consumer access. NORML has endorsed it as a step toward full federal legalization. Opposition comes from prohibitionist groups like Smart Approaches to Marijuana (SAM), which argues that interstate commerce would create a "Big Marijuana" industry akin to Big Tobacco, with national brands and aggressive marketing.

Legal and Regulatory Framework

The legal status of cannabis interstate commerce hinges on the interaction of the Controlled Substances Act, the Commerce Clause, the Tenth Amendment, and emerging state-level reciprocity agreements. Under current law, 21 U.S.C. § 841 criminalizes the interstate distribution of any Schedule I controlled substance. Even if both the origin and destination states have legalized cannabis, the product crosses federal jurisdiction during transport, triggering federal law. The Supremacy Clause, Article VI, Clause 2 of the Constitution, establishes that federal law preempts conflicting state law. Thus, a California-to-Oregon cannabis shipment, even between two legal states, constitutes a federal felony. The dormant Commerce Clause doctrine, developed through Supreme Court cases like Pike v. Bruce Church, Inc. (1970) and Philadelphia v. New Jersey (1978), holds that states cannot enact laws that discriminate against or unduly burden interstate commerce, even in the absence of federal legislation. If cannabis is rescheduled to Schedule III, legal scholars argue that state laws prohibiting interstate commerce could be challenged as protectionist barriers. However, the Supreme Court has also recognized a "market participant exception," allowing states to favor in-state businesses when the state itself is a market participant (e.g., operating state-run dispensaries). The application to cannabis remains untested. Several states have explored reciprocity agreements. In 2023, Oregon and California signed a Memorandum of Understanding (MOU) to study interstate cannabis commerce, but the agreement contained no binding commitments. Washington's Liquor and Cannabis Board proposed a framework in 2024 that would allow licensed producers to ship to other states with equivalent regulatory standards, but the proposal stalled amid concerns about federal enforcement. The Tenth Amendment reserves to the states all powers not delegated to the federal government. Some legal theorists argue that if the federal government declines to enforce the CSA against state-legal cannabis (as it largely did during the Cole Memo era), states have the sovereign authority to regulate commerce, including interstate commerce, within their borders. This argument has not been tested in court and faces significant skepticism given Gonzales v. Raich. If the DEA finalizes Schedule III rescheduling, cannabis businesses could theoretically register with the DEA as manufacturers and distributors under 21 C.F.R. § 1301, which governs Schedule III substances. However, the DEA has never issued such registrations for cannabis, and the agency could impose conditions that effectively prohibit interstate commerce. Additionally, Schedule III substances are subject to the Federal Food, Drug, and Cosmetic Act, giving the Food and Drug Administration (FDA) jurisdiction over labeling, testing, and marketing — a regulatory layer the cannabis industry has never navigated.

State-by-State Breakdown of Interstate Commerce Positions

California

California legalized adult-use cannabis in 2016 via Proposition 64, creating the world's largest legal market with $5.3 billion in sales in 2023. The state faces chronic oversupply, with wholesale flower prices at $400-700 per pound in 2025, down from $1,500 in 2018. The California Department of Cannabis Control has participated in interstate commerce working groups and expressed openness to reciprocal agreements, but state law currently prohibits any export. Possession limit: 28.5 grams of flower, 8 grams of concentrate. Key statute: Business and Professions Code § 26000 et seq.

Colorado

Colorado launched adult-use sales in January 2014 under Amendment 64. The state has a mature, stable market with $1.5 billion in annual sales and wholesale prices of $800-1,200 per pound. Colorado's Marijuana Enforcement Division has studied interstate commerce but taken no formal position. The state benefits from tourism-driven demand and has less economic pressure to export than California or Oregon. Possession limit: 28 grams of flower, 8 grams of concentrate. Key statute: Colorado Revised Statutes § 44-10-101 et seq.

Oregon

Oregon legalized adult-use cannabis in 2014 via Measure 91. The state issued over 2,000 cultivation licenses for a population of 4.2 million, creating massive oversupply. Wholesale prices dropped to $200-400 per pound by 2024, forcing hundreds of growers into bankruptcy. Oregon has the strongest economic incentive to pursue interstate commerce and has signed MOUs with California to study the issue. Possession limit: 28 grams of flower in public, unlimited at home. Key statute: Oregon Revised Statutes § 475B.

New York

New York legalized adult-use cannabis in 2021 via the Marijuana Regulation and Taxation Act (MRTA). Retail sales began in late 2022, but the market remains undersupplied due to slow licensing. Wholesale prices exceed $2,500 per pound, and consumers pay $50-70 per eighth. New York has not authorized interstate commerce and benefits from a protected market that shields in-state cultivators from competition. Possession limit: 85 grams of flower. Key statute: Cannabis Law § 3.

Oklahoma

Oklahoma legalized medical cannabis in 2018 via State Question 788, creating one of the most permissive licensing regimes in the nation. The state issued over 9,000 cultivation licenses, producing an estimated 1.5 million pounds of excess flower annually. Wholesale prices collapsed to $150-300 per pound by 2024. Oklahoma cultivators are among the most vocal advocates for interstate commerce, seeing it as the only path to financial viability. Possession limit: 3 ounces for medical patients. Key statute: Oklahoma Statutes Title 63, § 420 et seq.

Massachusetts

Massachusetts legalized adult-use cannabis in 2016 via Question 4. The state has a tightly regulated market with high barriers to entry, including a $1.5 million net worth requirement for applicants. Wholesale prices remain elevated at $1,800-2,400 per pound. Massachusetts has not expressed interest in interstate commerce and benefits from a protected market. Possession limit: 28 grams. Key statute: Massachusetts General Laws Chapter 94G.

Michigan

Michigan legalized adult-use cannabis in 2018 via Proposal 1. The state has rapidly expanded, with over 1,500 licensed retailers by 2024. Wholesale prices are moderate at $900-1,400 per pound. Michigan has not taken a position on interstate commerce but could benefit from exporting to undersupplied Midwest markets. Possession limit: 71 grams. Key statute: Michigan Regulation and Taxation of Marihuana Act.

Market and Business Implications

Interstate commerce would trigger the most significant capital reallocation in cannabis industry history, with an estimated $15-20 billion in stranded assets and $30-40 billion in new investment opportunities over five years. MSOs would face a strategic fork. Vertically integrated operators like Curaleaf and Trulieve, which have invested heavily in state-specific cultivation, would need to decide whether to consolidate production in low-cost states (California, Oklahoma, Oregon) and shutter redundant facilities, or maintain distributed operations to preserve supply chain control and hedge against regulatory uncertainty. A 2025 analysis by Viridian Capital Advisors estimated that full interstate commerce could reduce MSO cultivation footprints by 40-60%, freeing up $8-12 billion in capital for retail expansion, brand development, or debt reduction. Wholesale pricing would undergo violent convergence. California outdoor flower at $300 per pound and New York indoor at $2,800 per pound cannot coexist in an open market. Analysts project a national equilibrium price of $800-1,200 per pound for premium indoor flower within 24 months of interstate commerce authorization, with outdoor and greenhouse flower settling at $300-500 per pound. This would devastate high-cost cultivators in Massachusetts, New York, Illinois, and New Jersey, while rewarding efficient operators in California, Oregon, and Oklahoma. Hundreds of small cultivators in protected markets would face bankruptcy. Retail prices would drop 20-40% in undersupplied states, expanding the total addressable market. A 2024 study by New Frontier Data estimated that a 30% price reduction in New York, New Jersey, and Pennsylvania could increase total cannabis sales in those states by 50-70% as consumers shift from the illicit market. However, state tax revenues could decline if lower prices reduce the tax base, unless states shift from ad valorem (percentage-of-price) taxes to weight-based or THC-based taxes. Transportation and logistics emerge as a multi-billion-dollar opportunity. Companies like Nabis (California distribution), Acreage Logistics, and traditional freight carriers like FedEx or UPS (if federal law permits) could build national cannabis supply chains. Specialized cold-chain logistics for concentrates and edibles, compliance-focused tracking systems, and interstate insurance products would create entirely new service sectors. Testing laboratories face consolidation. Currently, every state requires in-state testing for potency, pesticides, heavy metals, and microbials. Interstate commerce could enable centralized testing hubs, reducing costs but also eliminating hundreds of local lab jobs. The question of whether the destination state, origin state, or both require testing remains unresolved. Section 280E of the Internal Revenue Code, which prohibits cannabis businesses from deducting ordinary business expenses because cannabis is a Schedule I or II controlled substance, would be partially alleviated if cannabis moves to Schedule III. This would improve MSO profitability by 15-30%, according to estimates by Viridian Capital, freeing up capital for expansion into interstate commerce.

What Experts Say

Legal scholars, industry executives, and regulators are divided on the timeline and structure of interstate cannabis commerce, but most agree it is inevitable within the next five years. According to Robert Mikos, a professor at Vanderbilt Law School and author of "Marijuana Law, Policy, and Authority," the dormant Commerce Clause provides the strongest legal pathway once cannabis is rescheduled. In a 2025 law review article, Mikos argued that state laws prohibiting interstate commerce would likely fail constitutional scrutiny under Pike v. Bruce Church if cannabis is Schedule III, because the burden on interstate commerce (duplicated infrastructure, price disparities) would outweigh any legitimate local interest in controlling supply chains. Hilary Bricken, a cannabis attorney and chair of the Cannabis Practice Group at Harris Bricken, has cautioned that rescheduling alone does not authorize interstate commerce. In a 2024 interview with MJBizDaily, Bricken said that state-licensed operators would still need DEA registration as manufacturers and distributors, which the agency has never granted for cannabis. She predicted that the DEA would impose conditions such as federal quality standards, batch testing, and product tracking that most state-licensed operators could not meet without significant investment. David Culver, senior vice president of government relations at Canopy Growth, has advocated for a federal interstate commerce framework modeled on alcohol regulation. In testimony before the House Judiciary Committee in 2023, Culver proposed that Congress establish a federal cannabis agency analogous to the Alcohol and Tobacco Tax and Trade Bureau (TTB), which would license interstate shippers, enforce quality standards, and coordinate with state regulators. He argued that a patchwork of state-by-state reciprocity agreements would create chaos and favor large operators with legal resources to navigate complexity. Andrew Freedman, a former director of cannabis coordination for Colorado and now a consultant, has warned that interstate commerce could destabilize state markets and trigger a race to the bottom on quality and safety standards. In a 2025 op-ed in Politico, Freedman wrote that without federal baseline standards for pesticide limits, potency testing, and packaging, interstate commerce could enable low-quality products from permissive states to flood markets with stricter consumer protections. According to a 2024 survey by the National Cannabis Industry Association, 62% of cannabis business owners support interstate commerce, but support drops to 38% among operators in states with limited licenses or high barriers to entry. The survey found that cultivators in California, Oregon, and Oklahoma overwhelmingly favor interstate commerce (84%), while cultivators in New York, Massachusetts, and Illinois oppose it (71%).

What's Next: Timeline and Decision Points

The path to legal interstate cannabis commerce depends on three parallel tracks: DEA rescheduling, congressional legislation, and state-level reciprocity agreements, with critical decision points expected in late 2026 and throughout 2027. The DEA rescheduling process is the most immediate catalyst. The agency published its NPRM in May 2024 and received over 43,000 comments during the 60-day window. The DEA must now review comments, finalize the rule, and publish it in the Federal Register. Legal experts expect a final rule in Q4 2026 or Q1 2027. If cannabis moves to Schedule III, the industry will immediately test the boundaries — expect declaratory judgment actions in federal court seeking clarity on whether state-licensed operators can engage in interstate commerce without DEA registration. Congressional action remains uncertain. The 119th Congress (2025-2027) has seen reintroduction of the STATES Act, the SAFE Banking Act, and the Cannabis Administration and Opportunity Act (CAOA), which would deschedule cannabis and establish a federal regulatory framework. However, none have advanced to a floor vote as of July 2026. The 2026 midterm elections could shift the balance, particularly if cannabis legalization becomes a campaign issue in swing states. State-level reciprocity agreements are advancing slowly. California, Oregon, and Washington have formed a West Coast Cannabis Compact working group to study interstate commerce, with a target of publishing a model framework by December 2026. The framework is expected to include mutual recognition of licenses, harmonized testing standards, and a tax-sharing agreement. However, implementation would still require federal authorization or a legal strategy to avoid CSA violations. Industry test cases are likely. Glass House Brands' July 2026 announcement suggests that at least one operator is preparing to move product across state lines, either through a legal challenge, a pilot program with state authorization, or reliance on a novel interpretation of the law. If Glass House or another operator successfully completes an interstate shipment without federal prosecution, it could trigger a cascade of similar moves. Key dates to watch: - Q4 2026: Expected DEA final rule on rescheduling - December 2026: West Coast Cannabis Compact framework publication - Q1 2027: Potential congressional floor votes on SAFE Banking or CAOA - Q2 2027: First legal challenges to state prohibitions on interstate commerce under dormant Commerce Clause - 2028: Potential Supreme Court case if lower courts split on constitutionality of state bans

Further Reading and Primary Sources

• Controlled Substances Act, 21 U.S.C. § 801 et seq. — https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13.pdf
• DEA Notice of Proposed Rulemaking on Cannabis Rescheduling (May 2024) — https://www.federalregister.gov/
• Gonzales v. Raich, 545 U.S. 1 (2005) — https://supreme.justia.com/cases/federal/us/545/1/
• California Department of Cannabis Control — https://cannabis.ca.gov/
• Oregon Liquor and Cannabis Commission — https://www.oregon.gov/olcc/
• National Cannabis Industry Association Policy Positions — https://thecannabisindustry.org/
• Viridian Capital Advisors Cannabis Deal Tracker — https://www.viridianca.com/
• New Frontier Data Market Reports — https://newfrontierdata.com/
• Robert Mikos, "Marijuana Law, Policy, and Authority" (Wolters Kluwer, 2023)
• Congressional Research Service, "Marijuana: Medical and Retail — Selected Legal Issues" (2024) — https://crsreports.congress.gov/
• Federation of Tax Administrators, Cannabis Taxation Database — https://www.taxadmin.org/
• MJBizDaily Industry Analysis and News — https://mjbizdaily.com/